← Eichor
Study identifier: NCT05842161 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

South Africa Smoking Cessation and Engagement in HIV/TB Care Care

Condition: HIV Infections · Tuberculosis · Smoking Cessation  ·  Sponsor: Massachusetts General Hospital

PhaseNA
Planned participants86
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings.

This description comes directly from the study's public registry record.

Talk to the study team

Conall O'Cleirigh, PhD  ·  617-643-0385  ·  cocleirigh@mgh.harvard.edu

Brianna A Estrada, BS  ·  617-643-2147  ·  bestrada@mgh.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Cape TownRondebosch, South AfricaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05842161